Summary
We have recently shown that cyclosporin A (CsA) reverses pleiotropic drug resistance in human acute lymphatic leukemia in vitro and daunorubicin resistance in Ehlrich ascites tumor in vivo. In the present study we examined the mechanisms by which CsA might reverse pleiotropic drug resistance relative to changes in cellular plasma membrane potentials and intracellular calcium ([Ca2+]i). Membrane potentials were measured with DIOC5 dye flowcytometrically and [Ca2+]i levels with Quin 2 dye spectrofluorimetrically. All pleiotropic (PDR) drug-resistant tumor sublines had decreased membrane potentials (membrane depolarized) compared with their corresponding drug-sensitive parental tumors. In comparison, the membrane potentials of a control antimetaboliteresistant acute leukemia cell line were unchanged. The basal levels of [Ca2+]i in the PDR sublines were variable compared with those of parental drug-sensitive cell lines. Incubation of all PDR tumor sublines with CsA or verapamil resulted in the restoration of membrane potentials to that characteristic of the corresponding drug-sensitive parental tumor. Cyclosporin A produced variable changes in the levels of [Ca2+]i. These data suggest that alteration of membrane potentials is one of the mechanisms responsible for pleiotropic drug resistance in malignancy and show that this alteration is corrected by CsA and verapamil.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bashford CL, Micklem KJ, Pasternak CA (1985) Sequential onset of permeability changes in mouse ascites cells induced by Sendai virus. Biochim Biophys Acta 814:247
Beck WT (1983) Vinca alkaloid-resistant phenotype in cultured human leukemia lymphoblasts. Cancer Treat Rep 67: 875
Colombani PM, Robb A, Hess AD (1985) Cyclosporin A binding to calmodulin: A possible site of action on T lymphocytes. Science 228: 237
Damjanovich S, Aszalos A, Muihern S, Balazs M, Matyus L (1986) Cytoplasmic membrane potential of mouse lymphocyte is decreased by cyclosporins. Mol Immunol 23: 175
Davis S, Weiss MJ, Wong JR, Lampidis TJ, Chen LB (1986) Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 260: 13844
Dawe CJ, Potter M (1957) Morphologic and biologic progression of a lymphoid neoplasm of the mouse in vivo and in vitro. Am J Pathol 33: 603
Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW (1984) Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226: 544
Harker WG, Bauer D, Etiz BB, Newman RA, Sikic BI (1986) Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res 46:2369
Hasmann M, Valet GK, Tapiero H, Lampidis TJ (1987) Plasma and mitochondrial transmembrane potentials in adriamycin resistant and sensitive Friend leukemia cells as determined by flow cytometry. Proc Am Assoc Cancer Res 28: 283
Kessel D, Wilberding C (1985) Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res 45: 1687
Marx JL (1986) Drug resistance of cancer cell probed. Science 234: 818
Monroe J, Cambier J (1983) B cell activation: I. Anti-immunoglobulin-induced receptor. Cross-linking results in a decreased in the plasma membrane potential of murine B lymphocytes. J Exp Med 157: 2073
Nair S, Samy TSA, Krishan A (1985) Calcium, calmodulin and protein content of adriamycin resistant and sensitive P388 cells. Proc Am Assoc Cancer Res 26: 1365 a
Racker E, Wu LT, Westcott D (1986) Use of slow Ca2+ channel blockers to enhance inhibition by taxol of growth of drugsensitive and-resistant Chinese hamster ovary cells. Cancer Treat Rep 70: 275
Rogers KE, Carr BI, Tokes ZA (1983) Cell surface-mediated cytotoxicity of polymer bound adriamycin against drug resistant hepatocytes. Cancer Res 43: 2741
Sikic BI, Etiz BB, Harker WG, Anderson RL, Hahn GM (1985) Mechanisms of multidrug (pleiotropic) resistance in the human sarcoma cell line MES-SA. Proc Am Assoc Cancer Res 26: 1346 a
Slater LM, Murray SL, Wetzel MW, Wisdom RM, DuVall EM (1982) Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest 70: 1131
Slater LM, Murray SL, Wetzel MW, Sweet P, Stupecky M (1986 a). Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother Pharmacol 16: 50
Slater LM, Sweet P, Stupecky M, Gupta S (1986b) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia. J Clin Invest 77: 1505
Slater LM, Sweet P, Stupecky M, Wetzel MW, Gupta S (1986c) Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Brit J Cancer 54: 235
Triton TR, Yee G (1982) The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 217: 248
Tsien R, Pozzan T, Rink J (1982) Calcium homeostasis in intact lymphocytes. Cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator. J Cell Biol 94: 325
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967
Tsuruo H, Iida H, Tsukagoshi S, Sakurai Y (1982a) Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730
Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S, and Sakarai Y (1982b) Enhancement of vincristine-and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharmacol 31: 3138
Wagner BM (1987) Cell membrane damage: Search for a common pathway. Hum Pathol 18: 767
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vayuvegula, B., Slater, L., Meador, J. et al. Correction of altered plasma membrane potentials. Cancer Chemother. Pharmacol. 22, 163–168 (1988). https://doi.org/10.1007/BF00257315
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257315